Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice

MLA

Mohammad Reza Hatamnejad, et al. “Selective Serotonin Reuptake Inhibitors and Inflammatory Bowel Disease; Beneficial or Malpractice.” Frontiers in Immunology, vol. 13, June 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....049e5ac9aa20148388262f3f1a31cc2b&authtype=sso&custid=ns315887.

APA

Mohammad Reza Hatamnejad, Shaghayegh Baradaran Ghavami, Marzieh Shirvani, Mona Asghari Ahmadabad, Shabnam Shahrokh, Maryam Farmani, Ghazal Sherkat, Hamid Asadzadeh Aghdaei, & Mohammad Reza Zali. (2022). Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice. Frontiers in Immunology, 13.

Chicago

Mohammad Reza Hatamnejad, Shaghayegh Baradaran Ghavami, Marzieh Shirvani, Mona Asghari Ahmadabad, Shabnam Shahrokh, Maryam Farmani, Ghazal Sherkat, Hamid Asadzadeh Aghdaei, and Mohammad Reza Zali. 2022. “Selective Serotonin Reuptake Inhibitors and Inflammatory Bowel Disease; Beneficial or Malpractice.” Frontiers in Immunology 13 (June). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....049e5ac9aa20148388262f3f1a31cc2b&authtype=sso&custid=ns315887.